Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. (J Am Coll Cardiol 2016;67:1472-87)
countries. TAVR is a novel therapy that qualifies as a "breakthrough technology" in medicine for the following reasons: 1) it addresses an unmet clinical need in an important area of medicine not well served by current therapies; 2) it is an innovative device concept that has challenged traditional standards; 3) the clinical benefits have been carefully validated by evidence-based medicine clinical research; 4) the application has been "generalized" to the practicing medical community (sufficiently user-friendly); and 5) it has become elevated beyond territorial subspecialty medicine and resonates as a significant sociomedical cultural advance (e.g., the multidisciplinary "heart team" popularized by TAVR is now the preferred approach for the management of patients with complex cardiovascular disease).
The purpose of the present paper is to provide a selective update on the rapidly changing field of TAVR therapy. Although past achievements and current issues will be discussed, the main goal is to expand our vision and focus a lens on future expectations and possibilities for TAVR as an expanding therapy for patients with aortic valve disease. Table 1) . The characterization of these so-called "inoperable" patients (variously described as extreme-or prohibitive-risk patients) has been problematic, but a widely agreed upon descriptor has been the likelihood of >50% mortality at 30 days or irreversible morbidity after SAVR; this classification includes both patients with extensive medical comorbidities and those with anatomic factors (e.g., porcelain aorta or "hostile" chest) precluding standard surgery.
PAST ACHIEVEMENTS
The clinical data supporting this indication derive from several European registries (6) (7) (8) , 
all-cause mortality in both groups ( Figure 2A ) and a median survival for TAVR patients of 44.5 months compared with 40.6 months for SAVR patients (p ¼ 0.76) (15). Striking early and sustained functional improvements occurred after both TAVR and SAVR, such that 85% of TAVR patients and 81% of SAVR patients remained in New York Heart Association functional class I or II after 5 years. Because the durability of TAVR systems has been a concern, the 5-year echocardiographic studies analyzed by an independent core laboratory were reassuring; hemodynamic improvements, which were equivalent to surgery at 1 year, were sustained for the duration of the study. Specifically, at 5 years, the mean gradient across the transcatheter valve remained stable at 10.7 mm Hg and the mean aortic valve area was indicates a reduction in 30-day mortality from 6.3% to 2.2% ( Figure 4A ) and a reduction in strokes from 6.7% shifted toward simplification of the procedure; this strategy is now described as the "minimalist" Most studies, including the PARTNER and CoreValve 
FUTURE EXPECTATIONS CLINICAL OUTCOMES AND PROCEDURAL BENCHMARKS.
Looking forward, a progressive attitude to encourage optimal clinical outcomes after TAVR would favor the application of quality benchmarks. As an example, an optimal quality TAVR center in the future should be able to achieve the following outcomes in high-risk AS patients: 1) all-cause mortality of approximately 2% to 3% at 30 days and <10% at 1 year; 2) significant strokes at 30 days in <2%; 3) major vascular complications in <5%; 4) new permanent pacemakers in <10%; and 5) moderate or severe PVR in <5%. • Focus on symptom relief and palliation
• SAVR suboptimal
• TAVR expected to improve survival and quality of life (QoL)
• Both SAVR and TAVR expected to improve survival and QoL Patients with severe aortic stenosis present with a spectrum of comorbidities that influence the treatment options available to them. The heart team will choose the optimal treatment strategy for individual patients based on their age, frailty, and anatomic and clinical characteristics. For patients undergoing transcatheter aortic valve replacement (TAVR), the bar for the performance standard is set by surgical aortic valve replacement (SAVR). TAVR has evolved as the preferred treatment for high-risk and inoperable patients. *Because the durability of transcatheter heart valves and outcomes in lower risk patients require further studies, SAVR remains the treatment of choice for such patients. 38. Yang TH, Webb JG, Blanke P, et al. Incidence and severity of paravalvular aortic regurgitation with multidetector computed tomography nominal area oversizing or undersizing after transcatheter heart valve replacement with the
